1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement

NCT02756650 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Behcet Disease

Interventions

DRUG: Canakinumab

Sponsor

Novartis Pharmaceuticals